Impact of the interaction between the polymorphisms and hypermethylation of the CD36 gene on a new biomarker of type 2 diabetes mellitus: circulating soluble CD36 (sCD36) in Senegalese females

Table 4 Association between CD36 genotypes and the risk of type 2 diabetes mellitus

SNP CD36	Control	T2DM	Statistical calculations Chi²; OR; RR; 95% CI
SNP CD36	n = 50	n = 50	Statistical calculations Chi²; OR; RR; 95% CI
rs1761667
HWE_X²	0.33 (p = 0.57)	0.02 (p = 0.88)	p = 0.74
VA	0.32	0.29
Genotyping (%)
GG	24 (48%)	25 (50%)	Chi² = 0.04; p = 0.9
AA + AG	26 (52%)	25 (50%)
Allele (%)
A	32 (32%)	29 (29%)	OR = 0.79 [0.43–1.44]
G	68 (68%)	71 (71%)	RR = 0.89; 95% CI
rs3211867
HWE_X²	0.83 (0.36)	0.09 (p = 0.77)	p = 0.39
VA	0.36	0.36
Genotyping (%)
CC	19 (38%)	20 (40%)	Chi² = 0.04; p = 0.9
AA + AC	31 (62%)	30 (60%)
Allele (%)
A	35 (35%)	36 (36%)	OR = 1 [0.56–1.79]
C	65 (65%)	64 (64%)	RR = 1; 95% CI

HWE_X² Hardy–Weinberg Equilibrium, VA Variation Allelic, OR Odds Ratio, RR Relative risk, T2DM Type 2 Diabetes Mellitus

ISSN: 1755-8794